XML 27 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 9 - Stock-based Compensation
6 Months Ended
Jun. 30, 2017
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
(
9
)
STOCK-BASED COMPENSATION
 
As of
June 30, 2017,
we have unvested restricted stock awards and stock options granted under stock-based employee compensation plans that are described more fully in Note
12
to the consolidated financial statements in our
2016
Form
10
-K.
 

As of
June 30, 2017,
total unrecognized compensation expense related to unvested restricted stock awards and stock options was
$732.
The weighted average period over which this expense is expected to be recognized is
3.0
years. The following table shows the allocation of the compensation expense we recorded during the
three
and
six
months ended
June 30, 2017
and
2016,
respectively, related to stock-based compensation:
 
 
Three Months Ended
June 30,
Six Months Ended
June 30,
 
2017
2016
2017
2016
Cost of revenues
  $
1
    $
2
    $
4
    $
5
 
Selling expense
   
-
     
2
     
-
     
3
 
Engineering and product development expense
   
1
     
3
     
4
     
5
 
General and administrative expense
   
96
     
132
     
178
     
165
 
    $
98
    $
139
    $
186
    $
178
 
 
There was
no
stock-based compensation expense capitalized in the
six
months ended
June 30, 2017
or
2016.


Restricted Stock Awards

We record compensation expense for restricted stock awards based on the quoted market price of our stock at the grant date and amortize the expense over the vesting period. Restricted stock awards generally vest over
four
years. However, during
January 2016,
we granted
22,500
shares of restricted stock to
three
of our independent directors which vested
100%
upon the re-election of these directors at our annual meeting of stockholders in
June 2016.
The total compensation expense related to the shares granted in
2016
was
$98,
and it was recorded upon the re-election of these directors. In
March 2017,
we granted
22,500
shares of restricted stock to these same directors. These shares vested
25%
upon the grant date and will vest an additional
25%
at each of
June 30,
September 30,
and
December 31, 2017.
The total compensation expense related to these shares is
$143
and it will be recorded as the shares vest during
2017.


The following table summarizes the activity related to unvested shares of restricted stock for the
six
months ended
June 30, 2017:
 
 

Number
of Shares
Weighted
Average
Grant Date
Fair Value
Unvested shares outstanding, January 1, 2017
   
97,025
    $
4.04
 
Granted
   
55,000
     
6.35
 
Vested
   
(34,725
)    
4.55
 
Forfeited
   
-
     
-
 
Unvested shares outstanding, June 30, 2017
   
117,300
     
4.97
 
 
The total fair value of the shares that vested during the
six
months ended
June 30, 2017
and
2016
was
$197
and
$138,
respectively, as of the vesting dates of these shares.

Stock Options

We record compensation expense for stock options based on the fair market value of the options as of the grant date.
No
option
may
be granted with an exercise period in excess of
ten
years from the date of grant. Generally, stock options will be granted with an exercise price equal to the fair market value of our stock on the date of grant and will vest over
four
years.

The fair value for stock options granted during the
six
months ended
June 30, 2017
and
2016
was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:
 
 
2017
2016
Risk-free interest rate
   
2.14
%    
1.30
%
Dividend yield
   
0.00
%    
0.00
%
Expected common stock market price volatility factor
   
.39
     
.40
 
Weighted average expected life of stock options (years)
   
6
     
4
 
 
The per share weighted average fair value of stock options issued during the
six
months ended
June 30, 2017
and
2016
was
$2.64
and
$1.43,
respectively.

The following table summarizes the activity related to stock options for the
six
months ended
June 30, 2017:
 
 

Number
of Shares
Weighted
Average
Grant Date
Fair Value
Options outstanding, January 1, 2017 (none exercisable)
   
19,800
    $
4.37
 
Granted
   
96,000
     
6.35
 
Exercised
   
-
     
-
 
Forfeited
   
-
     
-
 
Options outstanding, June 30, 2017 (4,950 exercisable)
   
115,800
     
6.01